FDAsafety guidance92% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (her2) as Boehringer Ingelheim; the shared HER2 mechanism makes the regulatory bar more directly transferable.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · HER2 Alterations
- Sub-indication
- HER2
Related signal: Boehringer Ingelheim's Zongertinib Trial Targets Advanced Cancers with HER2 Alterations